Rhumbline Advisers Sells 8,857 Shares of Roche Holding AG (OTCMKTS:RHHBY)

Rhumbline Advisers trimmed its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY) by 8.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,878 shares of the company’s stock after selling 8,857 shares during the period. Rhumbline Advisers’ holdings in Roche were worth $3,484,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in RHHBY. Bard Financial Services Inc. lifted its stake in shares of Roche by 156.8% during the 3rd quarter. Bard Financial Services Inc. now owns 80,500 shares of the company’s stock worth $3,216,000 after purchasing an additional 49,150 shares during the last quarter. Verity Asset Management Inc. bought a new position in Roche in the third quarter worth about $253,000. IHT Wealth Management LLC purchased a new stake in shares of Roche during the third quarter valued at about $236,000. Confluence Investment Management LLC boosted its holdings in shares of Roche by 26.3% in the 4th quarter. Confluence Investment Management LLC now owns 13,981 shares of the company’s stock valued at $488,000 after buying an additional 2,910 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS grew its position in shares of Roche by 1.3% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 136,923 shares of the company’s stock worth $5,490,000 after buying an additional 1,798 shares during the last quarter.

Roche Trading Up 0.7 %

OTCMKTS RHHBY opened at $41.74 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86. Roche Holding AG has a 12-month low of $29.20 and a 12-month high of $42.43. The company has a fifty day simple moving average of $38.24 and a two-hundred day simple moving average of $38.42.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a research note on Thursday, January 30th. Morgan Stanley initiated coverage on Roche in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, UBS Group raised Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Roche currently has a consensus rating of “Hold”.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.